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patients were initiated on 25mg of RLAI. At 12-months 63% 
of patients were still on RLAI. The reasons for discontinuation
were lack of response (14%); loss-to-follow-up (10.5%); other
(7.5%); patient or family choice (6%); adverse events (6%); tol-
erability (2%); and adherence (1.5%). Young age at schizophre-
nia onset and suicidal behavior at baseline were signiﬁcant risk
factors for time to discontinuation (p < 0.04). CONCLUSIONS:
The treatment continuation rate with RLAI at 12-months is con-
sistent with the results of Fleischhacker et al (2003), but supe-
rior to oral typical and atypical agents (Lieberman et al, 2005).
Fleischhacker et al (2003); J Clin Psychiatry 64(10):1250–1257.
Lieberman et al (2005); NEJM 353:1209–23.
PMH4
META-ANALYSIS OF SNRIS, SSRIS,AND TCAS IN THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER USING
REMISSION AS THE CLINICAL OUTCOME
Machado M1, Iskedjian M2, Einarson TR3
1Universidad de Chile, Santiago, RM, Chile, 2PharmIdeas Research and
Consulting Inc, Oakville, ON, Canada, 3University of Toronto,Toronto,
ON, Canada
OBJECTIVE: To summarize rates of clinical remission and
dropouts/withdrawal due to adverse drug reactions (ADRs) or
lack of efﬁcacy/effectiveness (LoE) of serotonin-norepinephrine
reuptake inhibitors (SNRIs), selective serotonin reuptake inhibi-
tors (SSRIs) and tricyclic antidepressants (TCAs). METHODS:
We searched Medline, Embase, International Pharmaceutical
Abstracts, and The Cochrane International Library from 1980
to 2005 for clinical trials using MeSH terms “serotonin norepi-
nephrine reuptake inhibitors”, “selective serotonin reuptake
inhibitors”, “tricyclic antidepressants”, “major depression”, and
“clinical remission”. Accepted languages were English, French,
German, Portuguese, and Spanish. A meta-analytic approach
was used to synthesize outcome rates from published head-to-
head clinical trials comparing two or more drugs (in therapeutic
doses) from SNRIs, and/or SSRIs, and/or TCAs from 6 to 12
weeks of treatment. Remission was deﬁned as a ﬁnal score = <7
on the Hamilton Depression Rating Scale or = <12 in the 
Montgomery-Asberg Depression Rating Scale. Data were 
combined across arms of individual studies using a random
effects model, producing point estimates with 95% conﬁdence
intervals. RESULTS: Data were gathered from 30 arms of 15
head-to-head trials of 2524 patients. TCAs had the highest
overall remission rate (45.7%), followed by SNRIs (45.0%), and
SSRIs (38.8%) (p > 0.05 for TCAs versus SNRIs; p < 0.001 for
TCAs versus SSRIs; and p < 0.001 for SNRIs versus SSRIs).
When patients were categorized as inpatients (n = 582) and out-
patients (n = 1613), SNRIs had the highest remission rate (52.0%
for 144 inpatients and 49.3% for 559 outpatients). SNRIs had
the lowest overall discontinuation rates (24.3%), followed by
SSRIs (27.1%), and TCAs (34.9%). Rates of discontinuation due
to ADRs and LoE were 9.8% and 5.2% for SNRIs, 7.3% and
7.0% for SSRIs, and 18.9% and 9.1% for TCAs, respectively. 
CONCLUSIONS: SNRIs have the highest efﬁcacy/effectiveness
remission rates (statistically signiﬁcant for inpatients and 
outpatients), and the lowest overall dropout/withdrawal rates 
suggesting clinical superiority for this class in treating major
depressive disorders.
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OBJECTIVE: While SGA therapy has been associated with new-
onset diabetes, the relative risk of the agents and the impact of
possible confounding variables have been questioned. This study
evaluated the impact of dose and treatment indication on the 
relative risk of new-onset diabetes associated with SGA therapy
while controlling for demographic, clinical and medication vari-
ables. METHODS: A retrospective database analysis capturing
electronic medical records for adult Texas Medicaid enrollees
taking antipsychotic monotherapy from January 1997 to 
December 2001, with a maximum follow-up of 12 months was
used. Patients were stratiﬁed according to treatment dose (low,
medium, high) and a hierarchy of mutually exclusive diagnostic
categories: schizophrenia, bipolar disorder, dementia, psychotic
disorder, non-psychotic disorder and no mental health indica-
tion. The incidence of diabetes was examined using multivariate
logistic regression analysis. RESULTS: Data were available for
13,731 patients. At treatment-onset, the prevalence of diabetes
was 16.9%. The mean (SD) dose by indication for the most
prevalent conditions (schizophrenia, bipolar disorder and
dementia, respectively) were as follows: olanzapine (12.04mg
(6.73); 8.91mg (5.78); 4.87mg (3.00)); quetiapine (273.16mg
(203.86); 146.33mg (142.29); 79.59 (82.57)); and risperidone
(3.55mg (2.37); 2.05 (1.76); 1.12 (0.85)). The overall incidence
of diabetes was 2.6%. Multivariate logistic regression analysis
showed no difference in the incidence of diabetes according to
the agent used (p = 0.281). Compared to risperidone, the odds
of new-onset diabetes were 0.879 (95% CI: 0.653 to 1.184) and
0.683 (95% CI: 0.414 to 1.126) for olanzapine and quetiapine,
respectively. Neither treatment indication (p = 0.876) nor
antipsychotic dose (p = 0.274) were associated with the devel-
opment of diabetes. CONCLUSIONS: Results indicate that the
risk of new-onset diabetes does not differ among SGA agents
(i.e., olanzapine, quetiapine and risperidone). While the dose of
antipsychotic prescribed varied signiﬁcantly according to treat-
ment indication and patient age, neither dose nor indication were
associated with the development of diabetes.
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OBJECTIVES: Atypical antipsychotic-induced diabetes has
raised concerns recently, while the extent of atypical 
antipsychotic-induced diabetes mellitus among Asians with
schizophrenia is not well known. This study aims to compare the
association of atypical antipsychotic treatments and diabetes
mellitus with that of haloperidol treatment and diabetes mellitus
among schizophrenic patients in Taiwan. METHODS: Data used
in this study came from Taiwan’s National Health Insurance
claims database for the period 2000–2004. This study identiﬁed
antipsychotic treatment episodes of clozapine, olanzapine,
risperidone, quetiapine, amisulpride, ziprasidone, and haloperi-
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dol. Inclusion criteria of treatment episodes were that the sub-
jects were aged 18 years or above, had had at least one admis-
sion due to schizophrenia during the two-year period prior to
the initiation of the treatment episodes, and with no diabetes
mellitus during a one-year period prior to the initiation of the
treatment episodes. Diabetes mellitus was identiﬁed by claims
with such diagnosis or with antidiabetic agents. A logistic regres-
sion model was applied to evaluate the likelihood of newly-onset
cases of diabetes of different antipsychotic treatment episodes.
Patient and clinical characteristics were included as covariates.
RESULTS: Compared with users of haloperidol, those receiving
clozapine, olanzapine, and risperidone had a higher probability
of developing diabetes mellitus. Those taking quetiapine, amisul-
pride, and ziprasidone, however, had no signiﬁcantly higher 
odds of developing diabetes mellitus. CONCLUSIONS: The pre-
liminary ﬁndings of this study support reports of atypical
antipsychotics-induced diabetes mellitus. Clozapine, olanzapine,
and risperidone, compared with haloperidol, are associated with
an increased risk of diabetes mellitus among schizophrenic
patients in Taiwan.
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OBJECTIVES: Describe the annual direct health care and indi-
rect work loss costs for employees treated with antidepressants
and compare them across patients with different treatment
response. METHODS: We examined 1999–2003 data from a
claims database of 1.2 million beneﬁciaries, from 7 large U.S.
employers. Analysis was restricted to employees aged 18–64,
with at least one diagnosis of major depressive disorder (ICD-9:
296.2x, 296.3x) and at least one prescription of selective 
serotonin or seratonin/norepinephrine reuptake inhibitor
(SSRI/SNRI). Patients were classiﬁed as combination antidepres-
sant therapy users, switchers, discontinuers, or monotherapy
maintainers. Annual direct health care costs, including drug and
medical costs (comprising inpatient, outpatient, and emergency
visits), and indirect work loss costs (comprising absenteeism and
disability) were calculated for the 12-month period following
therapy initiation. Results were compared descriptively across
treatment responses using t-tests and ANOVA analyses.
RESULTS: Of the 3971 patients, 18.4% were on combination
therapy, 19.7% switchers, 45.1% discontinuers, and 16.8%
monotherapy maintainers. Patients on combination therapy had
similar direct and indirect costs compared to switchers (all p >=
0.08). The average direct and indirect costs for patients on com-
bination therapy and switchers ($7986 and $2806 respectively)
were higher than those for discontinuers ($6013 and $1680
respectively, all p < 0.001) or maintainers ($5193 and $1467
respectively, all p < 0.001). Compared to patients on combina-
tion therapy and switchers, maintainers had similar drug costs
($1980 vs. $2068, p = 0.469). Compared to discontinuers, main-
tainers had higher drug costs ($1,980 vs. $1095, p < 0.001), but
lower medical ($3214 vs. $4918, p = 0.002) and disability costs
($360 vs. $664, p = 0.008). CONCLUSION: Patients on 
combination therapy or who switched monotherapy had higher
average direct health care costs and indirect work loss costs than
patients who discontinued or maintained therapy. Maintainers
had higher drug costs but lower medical and disability costs 
compared to discontinuers.
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OBJECTIVE: To estimate the incremental cost-effectiveness of
venlafaxine extended-release compared to Selective Serotonin
Reuptake Inhibitors (SSRIs) in the treatment of major depressive
disorder (MDD) in Canada. METHODS: A previously validated
decision-tree model for the treatment of MDD was adapted 
to the Canadian clinical practice setting. Probabilities used to
populate the decision-tree were derived from the literature and
where needed, from a Delphi panel consisting of two General
Practitioners and two Psychiatrists. The Ontario Ministry of
Health and Long-term Care perspective was used in this study.
The relevant direct medical costs (year 2005 Canadian dollar
values) were derived from the Ontario Health Insurance Policy
(OHIP) and the Ontario Case Costing Initiative (OCCI). The
drug acquisition cost for venlafaxine (brand) and SSRIs (generic)
was derived from the Ontario Drug Beneﬁt formulary (ODB).
The treatment goal in the model was achieving remission and the
primary outcome measure in the model was Symptom Free Days
(SFDs). The time horizon was six months; therefore the costs and
outcomes were not discounted. Various one-way sensitivity
analyses were performed. RESULTS: The average six-month
expected cost per patient for venlafaxine and SSRIs were
CDN$4156 and CDN$4224 respectively. The average six-month
expected SFDs were 53.4 and 46.7 days for venlafaxine and
SSRIs respectively. The cost-effectiveness as measured by cost per
SFDs was CDN$77.86 for venlafaxine and CDN$90.36 for
SSRIs. The incremental cost-effectiveness analysis showed a
treatment strategy using venlafaxine as ﬁrst line was dominant.
The sensitivity analysis demonstrated the results robustness to
variations in drug acquisition cost. CONCLUSION: Despite a
higher drug acquisition cost, venlafaxine extended-release may
be cost-effective and even cost saving compared to SSRIs when
used as ﬁrst line treatment of MDD in a Canadian clinical 
practice setting.
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OBJECTIVES: To estimate the cost-effectiveness of atypical
antipsychotics (AAPs) in the treatment of acute mania in patients
with bipolar I disorder from a managed care perspective.
METHODS: The model estimated the cost-effectiveness (CE)
ratios for each AAP when used as monotherapy for the acute (3-
week) treatment of patients with bipolar mania. CE ratios were
deﬁned as the total annual cost per responder, and responders
were deﬁned as patients with a 50% improvement on the 
YMRS scale at 3 weeks. Data sources included published litera-
ture, package inserts, and primary data analysis of a managed
care claims database. The median response rate for each AAP
was used in the base case scenario; 45.5%, 50.0%, 58.0%,
53.3%, and 56.7% for aripiprazole, ziprasidone, risperidone,
quetiapine, and olanzapine, respectively. Since there are no pub-
